Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(thromboprophylaxis)
4,504 results
  • Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature. [Journal Article]
    Thromb J 2019; 17:23Papadakis E, Pouliakis A, … Grouzi E
  • CONCLUSIONS: LMWHs are used extensively during pregnancy and puerperium in Greece for VTE treatment and prophylaxis and for a variety of other indications as well. Although the drug has been shown to be both safe and efficacious, its use for some indications has no proven scientific evidence. In order to clearly define the role of LMWHs in pregnancy, beyond thromboprophylaxis, large prospective studies are required, which could be based on the conclusions of this study.
  • Venous thromboembolism in cancer patients: Still looking for answers. [Review]
    Exp Ther Med 2019; 18(6):5026-5032Iorga RA, Bratu OG, … Diaconu CC
  • Patients with cancer-associated venous thromboembolism (VTE) represent a real challenge in clinical practice. Patients with cancer have a greater risk both of VTE and bleeding. There are only a few studies regarding the therapeutic approach of VTE in patients with cancer, especially after cancer surgery, and on thromboprophylaxis during chemotherapy. Many of the anticoagulation therapy recommenda…
  • Obesity And Obstetric Anesthesia: Current Insights. [Review]
    Local Reg Anesth 2019; 12:111-124Taylor CR, Dominguez JE, Habib AS
  • Obesity is a significant global health problem. It results in a higher incidence of complications for pregnant women and their neonates. Cesarean deliveries are more common in obese parturients as well. The increased burden of comorbidities seen in this population, such as obstructive sleep apnea, necessitates antepartum anesthetic consultation. These patients pose unique challenges for the pract…
  • Is there a role for low-dose DOACs as prophylaxis? [Journal Article]
    Hematology Am Soc Hematol Educ Program 2019; 2019(1):187-193Cohen AT, Hunt BJ
  • The direct oral anticoagulants (DOACs) have transformed the management of thrombotic disorders. Large clinical trials have demonstrated that DOACs can replace vitamin K antagonists (VKAs) in the 2 existing major indications for anticoagulation: the prevention of stroke in atrial fibrillation and the acute treatment and secondary prevention of venous thromboembolism (VTE); this literature is widel…
  • What's new in the prevention and treatment of cancer-associated thrombosis? [Journal Article]
    Hematology Am Soc Hematol Educ Program 2019; 2019(1):158-166Kimpton M, Carrier M
  • Venous thromboembolism (VTE) is a common complication in ambulatory cancer patients receiving chemotherapy. Current clinical guidelines recommend against the use of routine primary thromboprophylaxis in unselected ambulatory cancer patients. The Khorana score is a risk assessment tool derived and prospectively validated for the identification of cancer patients at high risk of thrombotic complica…
  • How I treat a refractory myeloma patient who is not eligible for a clinical trial. [Journal Article]
    Hematology Am Soc Hematol Educ Program 2019; 2019(1):125-136Leng S, Bhutani D, Lentzsch S
  • Myeloma patients not eligible for clinical trials have many treatment options. Choosing the next best therapy starts with careful assessment of the biology and dynamics of the disease at relapse, as well as the condition and situation of the patient. Fit patients should be considered for triplet regimens, whereas intermediate and frail patients warrant dose-reduced triplets or doublets. An indole…
New Search Next